Formosa
APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%)
APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%)
APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%), if approved, may have an advantageous profile in dosing frequency and side effects while reducing the inflammation and pain associated with ocular surgery.
Further leverages Eyenovia’s MydCombi sales force and represents additional near-term potential revenue source.
Eyenovia plans to evaluate novel clobetasol formulations in its proprietary Optejet® dispensing platform as a potential treatment for dry eye, estimated to be a $3.6 billion market in the U.S.